tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Passage Bio Reports Q3 Financial Results and Updates
PremiumCompany AnnouncementsPassage Bio Reports Q3 Financial Results and Updates
2M ago
Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)
Premium
The Fly
Passage Bio reports Q3 EPS ($2.44), consensus ($2.97)
2M ago
Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia
Premium
Company Announcements
Passage Bio’s PBFT02 Study: A Promising Step in Gene Therapy for Dementia
3M ago
Passage Bio Reports Promising Q2 2025 Financial Results
PremiumCompany AnnouncementsPassage Bio Reports Promising Q2 2025 Financial Results
5M ago
Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
Premium
The Fly
Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year
5M ago
Passage Bio expects cash to fund operations into Q1 of 2027
Premium
The Fly
Passage Bio expects cash to fund operations into Q1 of 2027
5M ago
Passage Bio announces 1-for-20 reverse stock split
PremiumThe FlyPassage Bio announces 1-for-20 reverse stock split
6M ago
Optimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns
Premium
Ratings
Optimistic Buy Rating for Passage Bio’s PBFT02: Promising Efficacy and Managed Safety Concerns
7M ago
Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating
Premium
Ratings
Passage Bio’s Promising Clinical Trial Results and Strategic Adjustments Justify Buy Rating
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100